A staff member tests samples of the COVID-19 inactivated vaccine at a vaccine production plant of China National Pharmaceutical Group (Sinopharm) in Beijing, capital of China, April 11, 2020. (ZHANG YUWEI / XINHUA)
A front-running COVID-19 vaccine candidate being developed in China is expected to be available as soon as the end of this year, according to a report published in the official Wechat account of the State-owned Assets Supervision and Administration Commission.
The vaccine, jointly developed by the Beijing Institute of Biological Products and China National Biotec Group Co., has completed phase II testing and may be ready for the market at the end of this year or early next year, said the report.
READ MORE: Xi: China to share vaccine with world
In total, five vaccines developed by Chinese companies are being tested on humans, the most in any country
The production line for the vaccine will be fully disinfected and closed in preparation for output to start Saturday, and will have a full manufacturing capacity of 100 million-120 million vaccines each year.
Drugmakers are racing to develop a cure for the contagion that has so far killed at least 365,000 people. More than 100 vaccines for the virus are being developed globally, but only a handful have made it to the crucial and final human clinical trial stage, with Chinese scientists leading the way.
In total, five vaccines developed by Chinese companies are being tested on humans, the most in any country. Beijing has mobilized its health authorities, drug regulators and research institutes to work around the clock with local companies to come up with the world’s first successful one for COVID-19.
The vaccine candidate from Beijing Institute of Biological Products and China National Biotec Group employs a killed version of the novel coronavirus that can still trigger an immune response. Such inactivated vaccines have been developed for many years to protect populations from diseases including polio and hepatitis.
While inactivated vaccines may be slower to develop initially, their familiar path to mass production might allow them to overtake shots made by newer, cutting-edge approaches.
ALSO READ: Chinese trial vaccine may be tested abroad
Copyright 1995 - 2020. All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily. Without written authorization from China Daily, such content shall not be republished or used in any form.
HONG KONG NEWS